This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2017 Feb 4;389(10068):e2.

doi: 10.1016/S0140-6736(17)30145-9. Epub 2017 Jan 21.

Department of Error

No authors listed

PMID: 28117089
DOI: 10.1016/S0140-6736(17)30145-9

Published Erratum

Department of Error

No authors listed. Lancet. 2017.

. 2017 Feb 4;389(10068):e2.

doi: 10.1016/S0140-6736(17)30145-9. Epub 2017 Jan 21.

PMID: 28117089
DOI: 10.1016/S0140-6736(17)30145-9

No abstract available

PubMed Disclaimer

Erratum for

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R. Smolen JS, et al. Lancet. 2016 Dec 3;388(10061):2763-2774. doi: 10.1016/S0140-6736(16)31651-8. Epub 2016 Nov 15. Lancet. 2016. PMID: 27863807 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations